RBX2660 could be a new option for people who experience recurrent, debilitating Clostridioides difficile infections. ACG2022
At the time of screening, about half of participants had a history of one or two infections withOf the 402 participants whose outcomes could be analyzed, 75% reported treatment success, meaning no furtherC difficile
For the subset of participants with inflammatory bowel disease, Khanna noted that the success rates were in the 80% range, which is higher than what is seen in clinic fecal microbiota transplantation programs.Of the participants, 63% reported treatment-emergent adverse events.
Fecal microbiota samples from a biobank are more standardized, but there have been intermittent shutdowns and availability has been limited during the pandemic, she said.